SuperworthSilexion Therapeutics EPS SLXN
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- $5.17
- −88% on a year earlier
Silexion Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was $5.17, down 88% on the same quarter a year before.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | $5.17 | −88% | |
| Q1 FY26 | $8.50 | −78% | |
| Q3 FY25 | $28.80 | −99% | |
| Q2 FY25 | $43.19 | −98% | |
| Q1 FY25 | $38.40 | −98% | |
| Q3 FY24 | $2742.50 | +160% | |
| Q2 FY24 | $1978.00 | −78% | |
| Q1 FY24 | $1843.50 | −56% | |
| Q3 FY23 | $1053.00 | n/a | |
| Q2 FY23 | $8842.50 | n/a | |
| Q1 FY23 | $4144.50 | n/a |
Against its peers
Companies in Biotechnology nearest Silexion Therapeutics' size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| SLXNSilexion Therapeutics | n/m |
| CRISCuris | −$14.22 |
| CLDICalidi Biotherapeutics | −$54.30 |
| VIVSVivoSim Labs, INC. | −$4.45 |
| PMCBPharmaCyte Biotech | −$2.40 |
| LIMNLiminatus Pharma | −$21.50 |
| AIMAIM ImmunoTech | −$1.00 |
| CELZCreative Medical Technology | −$1.97 |
| SNTISenti Biosciences | −$1.77 |
| INABIN8BIO | −$2.06 |
| INTSIntensity Therapeutics | −$4.89 |
| Peer median | −$3.42 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Silexion Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.